SWOG clinical trial number
SWOG-8733
Evaluations of Operable Bladder Cancer Patients with Pre-Operative Irradiation + 5-FU and Inoperable Patients With Irradiation + 5-FU Alone, Phase II, A Pilot Study for Patients Ineligible for SWOG-8710
Closed
Phase
Accrual
77%
Published
Abbreviated Title
Local Bladder
Activated
04/01/1988
Closed
02/15/1997
Research committees
Genitourinary Cancer
Publication Information Expand/Collapse
2008
Treatment options for muscle invasive urothelial cancer for patients who were not eligible for cystectomy or neoadjuvant chemotherapy with methotrexate, vinblastine, adriamycin, and cisplatin: report of Southwest Oncology Group trial 8733 [PMID18404692]
Other Clinical Trials
SWOG Clinical Trial Number
S2427
Single Arm Phase II Study of Bladder Preservation with Immunoradiotherapy after a Clinically Meaningful Response to Neoadjuvant Therapy in Patients with Muscle Invasive Bladder Cancer (BRIGHT)
Research Committee(s)
Genitourinary Cancer
Activated
09/04/2025
Accrual
1%
Open
Phase
SWOG Clinical Trial Number
CCTG-PR26
A Randomized Phase III Clinical Trial for the Addition of Docetaxel to Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response (TRIPLE-SWITCH)
Research Committee(s)
Genitourinary Cancer
Activated
01/30/2025
Open
Phase
SWOG Clinical Trial Number
S2312
A Phase III Study of Cabazitaxel with or without Carboplatin in Patients with metastatic castrate-resistant prostate cancer (mCRPC), Stratified by Aggressive Variant Signature
Research Committee(s)
Genitourinary Cancer
Activated
09/03/2024
Accrual
7%
Open
Phase